Drug Database · Clinicians

Alpelisib

Brands (1) PiviktoShow all

US brand (reference label): PIQRAY; not a Philippine-registered brand.

Antineoplastic agent [phosphatidylinositol-3-kinase (pi3k) inhibitor] PH FDA category

Rx · Prescription drug3 PH productsVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID b20b4e18-7a4b-4500-a08f-06c6dab0ee5b, version date October 28, 2026 (PIQRAY · Novartis Pharmaceuticals Corporation). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • PIQRAY is indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic…
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE PIQRAY is indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-authorized test following progression on or after an endocrine-based regimen. PIQRAY is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-authorized test following progression on or after an endocrine-based regimen.

(1, 2.1)

Contraindications

4 CONTRAINDICATIONS PIQRAY is contraindicated in patients with severe hypersensitivity to it or any of its components [see Warnings and Precautions (5.1)]. Severe hypersensitivity to PIQRAY or to any of its components. (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • Recommended Dosage: 300 mg orally once daily with food. (2.2)
  • For adverse reactions, consider dose interruption, dose reduction, or discontinuation. (2.3)
2.1 Patient Selection

2.1 Patient Selection Select patients for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer with PIQRAY, based on the presence of one or more PIK3CA mutations in tumor tissue or plasma specimens [see Clinical Studies (14)]. If no mutation is detected in a plasma specimen, test tumor tissue.

Information on FDA-authorized tests for the detection of PIK3CA mutations in breast cancer is available at: http://www.fda.gov/CompanionDiagnostics.

2.2 Dosage and Administration

2.2 Dosage and Administration The recommended dosage of PIQRAY is 300 mg orally once daily with food [see Clinical Pharmacology (12.3)] until disease progression or unacceptable toxicity occurs. Patients should take their dose of PIQRAY at approximately the same time each day. Swallow PIQRAY tablets whole (tablets should not be chewed, crushed or split prior to swallowing).

No tablet should be ingested if it is broken, cracked, or otherwise not intact. If a dose of PIQRAY is missed, it can be taken with food within 9 hours after the time it is usually taken. After more than 9 hours, skip the dose for that day. The next day, take PIQRAY at the usual time. If the patient vomits after taking a dose, advise the patient not to take an additional dose on that day, and to resume the dosing schedule the next day at the usual time.

When given with PIQRAY, the recommended dose of fulvestrant is 500 mg administered on Days 1, 15, and 29, and once monthly thereafter. Refer to the Prescribing Information for fulvestrant.

2.3 Dosage Modifications for Adverse Reactions

2.3 Dosage Modifications for Adverse Reactions The recommended dosage modifications for adverse reactions are listed in Table 1. Table 1: PIQRAY Dose Reduction Guidelines for Adverse Reactions 1 1 Only one dose reduction is permitted for pancreatitis. 2 If further dose reduction below 200 mg once daily is required, discontinue PIQRAY.

PIQRAY dose level Dose and schedule Number and strength of tablets Starting dose 300 mg once daily Two 150 mg tablets First-dose reduction 250 mg once daily One 200 mg tablet and one 50 mg tablet Second-dose reduction 200 mg once daily 2 One 200 mg tablet Tables 2, 3, 4, and 5 summarize recommendations for dose interruption, reduction, or discontinuation of PIQRAY in the management of specific adverse reactions. Cutaneous Adverse Reactions If a severe cutaneous adverse reaction (SCAR) is confirmed, permanently discontinue PIQRAY.

Do not reintroduce PIQRAY in patients who have experienced previous SCAR during PIQRAY treatment [see Warnings and Precautions (5.2)]. Table 2: Dosage Modification and Management for Rash and Severe Cutaneous Adverse Reactions (SCARs) 1 Grading according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2 For all grades of rash, consider consultation with a dermatologist. 3 Antihistamines administered prior to rash onset may decrease incidence and severity of rash based on the SOLAR-1 trial. [see Warnings and Precautions (5.1, 5.2)] Grade 1,2 Recommendation 3 Grade 1 (< 10% body surface area (BSA) with active skin toxicity) No PIQRAY dose adjustment required.

Initiate topical corticosteroid treatment. Consider adding oral antihistamine to manage symptoms. If active rash is not improved within 28 days of appropriate treatment, add a low dose systemic corticosteroid. If the etiology is SCAR, permanently discontinue PIQRAY. Grade 2 (10%-30% BSA with active skin toxicity) No PIQRAY dose adjustment required.

Initiate or intensify topical corticosteroid and oral antihistamine treatment. Consider low dose systemic corticosteroid treatment. If rash improves to Grade ≤ 1 within 10 days, systemic corticosteroid may be discontinued. If the etiology is SCAR, permanently discontinue PIQRAY. Grade 3 (e.g., severe rash not responsive to medical management) (> 30% BSA with active skin toxicity) Interrupt PIQRAY.

Initiate or intensify topical/systemic corticosteroid and oral antihistamine treatment. If the etiology is SCAR, permanently discontinue PIQRAY. If the etiology is not a SCAR, interrupt dose until improvement to Grade ≤ 1, then resume PIQRAY at next lower dose level. Grade 4 (e.g., severe bullous, blistering or exfoliating skin conditions) (any % BSA associated with extensive superinfection, with IV antibiotics indicated; life-threatening consequences) Permanently discontinue PIQRAY.

Hyperglycemia Before initiating treatment with PIQRAY, test fasting plasma glucose (FPG), HbA1c, and optimize blood glucose. Consider premedication with metformin prior to the initiation of PIQRAY in combination with fulvestrant based on patient risk factors for hyperglycemia, gastrointestinal tolerability, and clinical situation [see Warnings and Precautions (5.3) and Adverse Reactions (6.1)].

After initiating treatment with PIQRAY, monitor fasting glucose (FPG or fasting blood glucose) at least once every week for the first 2 weeks, then at least once every 4 weeks, and as clinically indicated. Monitor HbA1c every 3 months and as clinically indicated. In patients with risk factors for hyperglycemia, monitor fasting glucose more closely and as clinically indicated [see Warnings and Precautions (5.3)].

Table 3: Dosage Modification and Management for Hyperglycemia Abbreviation: ULN, upper limit of normal. 1 FPG/Fasting Blood Glucose/Grade levels reflect hyperglycemia grading according to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. 2 Initiate applicable anti-hyperglycemic medications, including metformin, SGLT2 inhibitors or insulin sensitizers (such as thiazolidinediones or dipeptidyl peptidase-4 inhibitors), and review respective prescribing information for dosing and dose titration recommendations, including local hyperglycemic treatment guidelines. Metformin was recommended in the SOLAR-1 trial with the following guidance: Initiate metformin 500 mg once daily.

Based on tolerability, metformin dose may be increased to 500 mg twice daily, followed by 500 mg with breakfast, and 1,000 mg with dinner, followed by further increase to 1,000 mg twice daily if needed [see Warnings and Precautions (5.3)]. 3 As recommended in the SOLAR-1 trial, insulin may be used for 1-2 days until hyperglycemia resolves. However, this may not be necessary in the majority of PIQRAY-induced hyperglycemia, given the short half-life of PIQRAY and the expectation of glucose levels normalizing after interruption of PIQRAY. [see Warnings and Precautions (5.3)] Fasting plasma glucose (FPG)/Fasting blood glucose values 1 Recommendation Dose modifications and management should only be based on fasting glucose values (FPG or fasting blood glucose).

Grade 1 Fasting glucose > ULN -160 mg/dL or > ULN -8.9 mmol/L No PIQRAY dose adjustment required. Initiate or intensify anti-hyperglycemic treatment 2. Grade 2 Fasting glucose > 160-250 mg/dL or > 8.9-13.9 mmol/L No PIQRAY dose adjustment required. Initiate or intensify anti-hyperglycemic treatment 2. If fasting glucose does not decrease to ≤ 160 mg/dL or 8.9 mmol/L within 21 days under appropriate anti-hyperglycemic treatment 2,3, reduce PIQRAY dose by 1 dose level and follow fasting glucose value specific recommendations.

Grade 3 > 250-500 mg/dL or > 13.9-27.8 mmol/L Interrupt PIQRAY. Initiate or intensify oral anti-hyperglycemic treatment 2 and consider additional anti-hyperglycemic medications 3 for 1-2 days until hyperglycemia improves, as clinically indicated. Administer intravenous hydration and consider appropriate treatment (e.g., intervention for electrolyte/ketoacidosis/hyperosmolar disturbances).

If fasting glucose decreases to ≤ 160 mg/dL or 8.9 mmol/L within 3 to 5 days under appropriate anti-hyperglycemic treatment, resume PIQRAY at 1 lower dose level. If fasting glucose does not decrease to ≤ 160 mg/dL or 8.9 mmol/L within 3 to 5 days under appropriate anti-hyperglycemic treatment, consultation with a physician with expertise in the treatment of hyperglycemia is recommended.

If fasting glucose does not decrease to ≤ 160 mg/dL or 8.9 mmol/L within 21 days following appropriate anti-hyperglycemic treatment 2,3, permanently discontinue PIQRAY treatment. Grade 4 > 500 mg/dL or > 27.8 mmol/L Interrupt PIQRAY. Initiate or intensify appropriate anti-hyperglycemic treatment 2,3 (administer intravenous hydration and consider appropriate treatment (e.g., intervention for electrolyte/ketoacidosis/hyperosmolar disturbances)), re-check fasting glucose within 24 hours and as clinically indicated.

If fasting glucose decreases to ≤ 500 mg/dL or 27.8 mmol/L, follow fasting glucose value-specific recommendations for Grade 3. If fasting glucose is confirmed at > 500 mg/dL or 27.8 mmol/L, permanently discontinue PIQRAY treatment. Diarrhea or Colitis Table 4: Dosage Modification and Management for Diarrhea or Colitis 1 Grading according to CTCAE Version 5.0. 2 For Grade 2 and 3 colitis, consider additional treatment, such as enteric-acting and/or systemic steroids. [see Warnings and Precautions (5.5)] Grade 1 Recommendation Grade 1 No PIQRAY dose adjustment is required.

Initiate appropriate medical therapy and monitor as clinically indicated. Grade 2 Interrupt PIQRAY dose until improvement to Grade ≤ 1, then resume PIQRAY at the same dose level. For recurrent Grade ≥ 2, interrupt PIQRAY dose until improvement to Grade ≤ 1, then resume PIQRAY at the next lower dose level. Initiate or intensify appropriate medical therapy and monitor as clinically indicated 2.

Grade 3 Interrupt PIQRAY dose until improvement to Grade ≤ 1, then resume PIQRAY at the next lower dose level. Initiate or intensify appropriate medical therapy and monitor as clinically indicated 2. Grade 4 Permanently discontinue PIQRAY. Other Toxicities Table 5: Dosage Modification and Management for Other Toxicities (Excluding Hyperglycemia, Rash and Severe Cutaneous Adverse Reactions, and Diarrhea or Colitis) 1 Grading according to CTCAE Version 5.0. 2 For Grade 2 and 3 pancreatitis, interrupt PIQRAY dose until improvement to Grade < 2 and resume at next lower-dose level.

Only one dose reduction is permitted. If toxicity reoccurs, permanently discontinue PIQRAY treatment. 3 For Grade 2 total bilirubin elevation, interrupt PIQRAY dose until improvement to Grade ≤ 1 and resume at the same dose if resolved in ≤ 14 days or resume at the next lower dose level if improved in > 14 days. Grade 1 Recommendation Grade 1 or 2 No PIQRAY dose adjustment is required.

Initiate appropriate medical therapy and monitor as clinically indicated 2,3. Grade 3 Interrupt PIQRAY dose until improvement to Grade ≤ 1, then resume PIQRAY at the next lower dose level. Grade 4 Permanently discontinue PIQRAY. Refer to the Prescribing Information of fulvestrant for dosage modification guidelines in the event of toxicity and for other relevant safety information.

Dosing: Altered kidney function

From the US FDA label · Renal impairment (use in specific populations)

8.6 Renal Impairment The effect of severe renal impairment (CLcr < 30 mL/min) on alpelisib pharmacokinetics is unknown [see Clinical Pharmacology (12.3)]. No dose adjustment is recommended for patients with mild to moderate renal impairment (CLcr 30 to < 90 mL/min).

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use The safety and efficacy of PIQRAY in pediatric patients have not been established. Animal Toxicity Data In a juvenile toxicity study, daily oral administration of alpelisib to juvenile rats from postnatal day (PND) 7 through PND 70 (approximately equivalent to neonatal through adulthood in humans) resulted in reduced body weights, decreased femur lengths, and adverse effects in the kidney in both sexes and delayed balanopreputial separation in males at 20 mg/kg/day (equivalent to exposure in humans at the recommended dose of 300 mg/day based on AUC).

Adverse renal effects included increased vascular/perivascular extracellular matrix deposition in small vessels and tubular degeneration/regeneration in the renal papilla and medulla. The adverse renal effects persisted following a 14-week recovery period. In a 4-week general toxicology study, rats administered alpelisib had growth plate thickening and decreased trabeculae of the knee joint, dentin thinning, and degenerative odontoblasts at the dose of 30 mg/kg/day (approximately 3 times the exposure in humans at the recommended dose of 300 mg/day based on AUC).

Dentin thinning/irregular dentin was also observed in the 13-week toxicology study in rats at the high dose of 20 mg/kg/day (equivalent to exposures in humans at the recommended dose of 300 mg/day based on AUC).

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Of 284 patients who received PIQRAY in the SOLAR-1 trial, 117 patients were ≥ 65 years of age and 34 patients were ≥ 75 years of age. In patients treated with PIQRAY plus fulvestrant, there was a higher incidence of Grade 3-4 hyperglycemia in patients ≥ 65 years of age (44%) compared to patients < 65 years of age (32%).

No overall differences in effectiveness of PIQRAY were observed between patients ≥ 65 years of age compared to younger patients. There are an insufficient number of patients ≥ 75 years of age to assess whether there are differences in safety or effectiveness. However, in the SOLAR-1 trial, an increase in the hyperglycemia adverse reactions (74% vs 66%) and Grade 3-4 (56% vs 36%) hyperglycemia were observed in patients ≥ 75 years of age compared to patients < 75 years of age, respectively [see Warnings and Precautions (5.3)].

Administration

2.2 Dosage and Administration The recommended dosage of PIQRAY is 300 mg orally once daily with food [see Clinical Pharmacology (12.3)] until disease progression or unacceptable toxicity occurs. Patients should take their dose of PIQRAY at approximately the same time each day. Swallow PIQRAY tablets whole (tablets should not be chewed, crushed or split prior to swallowing). No tablet should be ingested if it is broken, cracked, or otherwise not intact. If a dose of PIQRAY is missed, it can be taken with food within 9 hours after the time it is usually taken. After more than 9 hours, skip the dose for that day. The next day, take PIQRAY at the usual time. If the patient vomits after taking a dose, advise the patient not to take an additional dose on that day, and to resume the dosing schedule the next day at the usual time. When given with PIQRAY, the recommended dose of fulvestrant is 500 mg administered on Days 1, 15, and 29, and once monthly thereafter. Refer to the Prescribing Information for fulvestrant.

US FDA label

Dosage forms

Philippines

  • Daily dose) film-coated tablet: 150 mg + 150 mg (300 mg, 250 mg + 50 mg (250 mg
  • Daily dose): 200 mg Film-Coated Tablet (200 mg

Registered products in the Philippines

3 products registered with the Food and Drug Administration (FDA) Philippines list Alpelisib as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products3
Philippine FDA-registered products for Alpelisib
Package insert
PiviktoAlpelisib
150 mg + 150 mg (300 mg daily dose) Film-Coated TabletAlu/PVC/PCTFE Blister Pack x 7's (Box of 28's) [14-day supply]
RxVAT-exempt
Novartis Pharma Stein AGSwitzerland
Importer: Novartis Healthcare Philippines, Inc.
DR-XY47678
Jan 20, 2027
PiviktoAlpelisib
200 mg Film-Coated Tablet (200 mg Daily Dose)Alu/PVC/PCTFE Blister Pack x 7's (Box of 14's) [14-day supply]
RxVAT-exempt
Novartis Pharma Stein AGSwitzerland
Importer: Novartis Healthcare Philippines, Inc.
DR-XY47676
Jan 20, 2027
PiviktoAlpelisib
250 mg + 50 mg (250 mg daily dose) Film-Coated TabletAlu/PVC/PCTFE Blister Pack x 7's (Each blister pack contains 7 units of 200 mg Film Coated Tablet and 7 units of 50 mg Film-Coated Tablet in Box of 28's) [14-day supply]
RxVAT-exempt
Novartis Pharma Stein AGSwitzerland
Importer: Novartis Healthcare Philippines, Inc.
DR-XY47677
Jan 20, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Tablets: 50 mg, 150 mg, and 200 mg alpelisib 50 mg: Light pink, unscored, round and curved with beveled edges film-coated tablet, imprinted with “L7” on one side and “NVR” on the other side. 150 mg: Pale red, unscored, ovaloid and curved with beveled edges film-coated tablet, imprinted with “UL7” on one side and “NVR” on the other side. 200 mg: Light red, unscored, ovaloid and curved with beveled edges film-coated tablet, imprinted with “YL7” on one side and “NVR” on the other side. Tablets: 50 mg, 150 mg, and 200 mg

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • Severe Hypersensitivity: Permanently discontinue PIQRAY. Promptly initiate appropriate treatment. (5.1)
  • Severe Cutaneous Adverse Reactions (SCARs): PIQRAY can cause SCARs, including Stevens-Johnson syndrome (SJS), erythema multiforme (EM), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS). Interrupt PIQRAY for signs or symptoms of SCARs. Permanently discontinue PIQRAY if SCARs are confirmed. (5.2)
  • Hyperglycemia: PIQRAY can cause severe hyperglycemia, in some cases associated with hyperglycemic hyperosmolar non-ketotic syndrome (HHNKS) or ketoacidosis. Before initiating treatment with PIQRAY, test fasting plasma glucose (FPG), HbA1c, and optimize blood glucose. Consider premedication with metformin prior to the initiation of PIQRAY based on patient risk factors for hyperglycemia, gastrointestinal tolerability, and clinical situation. Use of metformin premedication prior to the initiation of PIQRAY decreases the incidence and severity of hyperglycemia, but increases the incidence and severity of nausea, vomiting, and diarrhea adverse reactions. After initiating treatment, monitor FPG and HbA1c periodically. Initiate or optimize anti-hyperglycemic medications as clinically indicated. Interrupt, reduce dose, or discontinue PIQRAY if severe hyperglycemia occurs. (2.3, 5.3, 6.1)
  • Pneumonitis: PIQRAY can cause severe …
5.1 Severe Hypersensitivity

5.1 Severe Hypersensitivity Severe hypersensitivity reactions, including anaphylaxis and anaphylactic shock, can occur in patients treated with PIQRAY. Severe hypersensitivity reactions were manifested by symptoms, including, but not limited to, dyspnea, flushing, rash, fever, or tachycardia. The incidence of Grade 3 and 4 hypersensitivity reactions was 0.7% [see Adverse Reactions (6)].

Angioedema has been reported in the postmarketing setting in patients treated with PIQRAY [see Adverse Reactions (6.2)]. Advise patients of the signs and symptoms of severe hypersensitivity reactions. Permanently discontinue PIQRAY in the event of severe hypersensitivity.

5.2 Severe Cutaneous Adverse Reactions

5.2 Severe Cutaneous Adverse Reactions Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS), erythema multiforme (EM), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) can occur in patients treated with PIQRAY. In the SOLAR-1 study, SJS and EM were reported in 0.4% and 1.1% of the patients, respectively [see Adverse Reactions (6.1)].

Drug reaction with eosinophilia and systemic symptoms (DRESS) was reported in patients treated with PIQRAY in the postmarketing setting [see Adverse Reactions (6.2)]. If signs or symptoms of SCARs occur, interrupt PIQRAY until the etiology of the reaction has been determined. Consultation with a dermatologist is recommended.

If a SCAR is confirmed, permanently discontinue PIQRAY. Do not reintroduce PIQRAY in patients who have experienced previous severe cutaneous adverse reactions during PIQRAY treatment. If a SCAR is not confirmed, PIQRAY may require dose modifications, topical corticosteroids, or oral antihistamine treatment as described in Table 2 [see Dosage and Administration (2.3)].

Advise patients of the signs and symptoms of SCARs (e.g., a prodrome of fever, flu-like symptoms, mucosal lesions, progressive skin rash, or lymphadenopathy).

5.3 Hyperglycemia

5.3 Hyperglycemia Severe hyperglycemia, in some cases associated with hyperglycemic hyperosmolar non-ketotic syndrome (HHNKS) or ketoacidosis has occurred in patients treated with PIQRAY. Fatal cases of ketoacidosis have occurred in the postmarketing setting. Hyperglycemia was reported in 65% of patients treated with PIQRAY.

Grade 3 (FPG > 250 to 500 mg/dL) and Grade 4 (FPG > 500 mg/dL) hyperglycemia was reported in 33% and 3.9% of patients, respectively. Ketoacidosis was reported in 0.7% of patients (n = 2) treated with PIQRAY. Among the patients who experienced Grade ≥ 2 (FPG ≥ 160 mg/dL) hyperglycemia, the median time to first occurrence of hyperglycemia was 15 days (range, 5 to 517 days).

In the 187 patients with hyperglycemia, 87% (163/187) were managed with anti-hyperglycemic medication, and 76% (142/187) reported use of metformin as single agent or in combination with other anti-hyperglycemic medication [i.e., insulin, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sulfonylureas]. In patients with Grade ≥ 2 hyperglycemia with at least 1 grade improvement (n = 153), median time to improvement from the first event was 8 days (range, 2 to 65 days).

In all patients with elevated FPG who continued fulvestrant treatment after discontinuing PIQRAY (n = 54), 96% (n = 52) of patients had FPG levels that returned to baseline. Before initiating treatment with PIQRAY, test fasting plasma glucose (FPG), HbA1c, and optimize blood glucose. After initiating treatment with PIQRAY, monitor fasting glucose (FPG or fasting blood glucose) at least once every week for the first 2 weeks, then at least once every 4 weeks, and as clinically indicated.

Monitor HbA1c every 3 months and as clinically indicated. Monitor fasting glucose more frequently for the first few weeks during treatment with PIQRAY in patients with risk factors for hyperglycemia, such as obesity (BMI ≥ 30), elevated FPG, HbA1c at the upper limit of normal or above, use of concomitant systemic corticosteroids, or age ≥ 75 [see Use in Specific Populations (8.5)].

If a patient experiences hyperglycemia after initiating treatment with PIQRAY, monitor fasting glucose as clinically indicated, and at least twice weekly until fasting glucose decreases to normal levels. During treatment with anti-hyperglycemic medication, continue monitoring fasting glucose at least once a week for 8 weeks, followed by once every 2 weeks and as clinically indicated.

Consider consultation with a healthcare practitioner with expertise in the treatment of hyperglycemia and counsel patients on lifestyle changes. The safety of PIQRAY in patients with Type 1 and uncontrolled Type 2 diabetes has not been established as these patients were excluded from the SOLAR-1 trial. Patients with a medical history of controlled Type 2 diabetes were included.

Patients with a history of diabetes mellitus may require intensified hyperglycemic treatment. Closely monitor patients with diabetes. Consider premedication with metformin prior to the initiation of PIQRAY in combination with fulvestrant based on patient risk factors for hyperglycemia, gastrointestinal tolerability, and clinical situation.

In the METALLICA study, use of metformin starting 7 days prior to the initiation of PIQRAY appeared to decrease the incidence and severity of hyperglycemia events, but increased the incidence and severity of nausea, vomiting, and diarrhea adverse reactions [see Adverse Reactions (6.1)]. Based on the severity of the hyperglycemia, PIQRAY may require dose interruption, reduction, or discontinuation as described in Table 3 [see Dosage and Administration (2.3)].

Advise patients of the signs and symptoms of hyperglycemia (e.g., excessive thirst, urinating more often than usual or higher amount of urine than usual, or increased appetite with weight loss).

5.4 Pneumonitis

5.4 Pneumonitis Severe pneumonitis, including acute interstitial pneumonitis and interstitial lung disease, can occur in patients treated with PIQRAY. Pneumonitis was reported in 1.8% of patients treated with PIQRAY. In patients who have new or worsening respiratory symptoms or are suspected to have developed pneumonitis, interrupt PIQRAY immediately and evaluate the patient for pneumonitis.

Consider a diagnosis of non-infectious pneumonitis in patients presenting with non-specific respiratory signs and symptoms, such as hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams and in whom infectious, neoplastic, and other causes have been excluded by means of appropriate investigations. Permanently discontinue PIQRAY in all patients with confirmed pneumonitis.

Advise patients to immediately report new or worsening respiratory symptoms.

5.5 Diarrhea or Colitis

5.5 Diarrhea or Colitis Severe diarrhea, resulting in dehydration and in some cases in acute kidney injury, can occur in patients treated with PIQRAY. Most patients (58%) experienced diarrhea during treatment with PIQRAY. Grade 3 diarrhea occurred in 7% (n = 19) of patients. Among patients with Grade 2 or 3 diarrhea (n = 71), the median time to onset was 46 days (range, 1 to 442 days).

In clinical trials, 63% of patients who experienced diarrhea required antidiarrheal medications (e.g., loperamide) to manage symptoms. Dose reductions of PIQRAY were required in 6% of patients, and 2.8% of patients permanently discontinued PIQRAY due to diarrhea. Colitis has been reported in the postmarketing setting in patients treated with PIQRAY [see Adverse Reactions (6.2)].

Monitor patients for diarrhea and additional symptoms of colitis, such as abdominal pain and mucus or blood in stool. Based on the severity of the diarrhea or colitis, PIQRAY may require dose interruption, reduction, or discontinuation as described in Table 4 [see Dosage and Administration (2.3)]. Advise patients to start antidiarrheal treatment, increase oral fluids, and notify their healthcare provider if diarrhea occurs while taking PIQRAY.

Patients with colitis may require additional treatment, such as enteric-acting and/or systemic steroids.

5.6 Embryo-Fetal Toxicity

5.6 Embryo-Fetal Toxicity Based on findings in animals and its mechanism of action, PIQRAY can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, oral administration of alpelisib to pregnant rats and rabbits during organogenesis caused adverse developmental outcomes, including embryo-fetal mortality (post-implantation loss), reduced fetal weights, and increased incidences of fetal malformations at maternal exposures based on area under the curve (AUC) that were ≥ 0.8 times the exposure in humans at the recommended dose of 300 mg/day.

Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with PIQRAY and for 1 week after the last dose. Advise male patients with female partners of reproductive potential to use condoms and effective contraception during treatment with PIQRAY and for 1 week after the last dose [see Use in Specific Populations (8.1, 8.3) and Clinical Pharmacology (12.1)].

Refer to the Prescribing Information of fulvestrant for pregnancy and contraception information.

Drug interactions

Drug interactions (US label) US FDA label

7 DRUG INTERACTIONS Strong CYP3A Inducers: Avoid coadministration. Consider an alternative concomitant drug with no or minimal potential to induce CYP3A. (7.1) BCRP Inhibitors: Avoid coadministration. If unable to use alternative drugs, closely monitor for increased adverse reactions. (7.1) 7.1 Effect of Other Drugs on PIQRAY Strong CYP3A Inducer Avoid coadministration of strong CYP3A inducers with PIQRAY and consider an alternative concomitant drug with no or minimal potential to induce CYP3A.

Alpelisib is a CYP3A substrate [see Clinical Pharmacology (12.3)]. Coadministration with a strong CYP3A inducer decreases alpelisib concentration [see Clinical Pharmacology (12.3)], which may reduce alpelisib effectiveness. BCRP Inhibitors Avoid coadministration of BCRP inhibitors with PIQRAY. If cannot avoid coadministration, monitor for increased adverse reactions.

Alpelisib is a BCRP substrate [see Clinical Pharmacology (12.3)]. Coadministration of PIQRAY with a BCRP inhibitor may increase alpelisib concentration [see Clinical Pharmacology (12.3)], which may increase the risk of adverse reaction.

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

Metabolism Alpelisib is primarily metabolized by chemical and enzymatic hydrolysis to form its metabolite BZG791 and followed by CYP3A mediated hydroxylation.

CYP3A-mediated metabolites (12%) and glucuronides amounted to approximately 15% of the dose.

Drug Interaction Studies Clinical Studies and Model-Informed Approaches Strong CYP3A Inhibitors : Alpelisib AUC is predicted to increase 1.4-fold or less following coadministration of repeat doses of ketoconazole (a strong CYP3A inhibitor).

Strong and Moderate CYP3A Inducers : Alpelisib C max decreased by 38% and AUC by 57% following coadministration of repeat doses of rifampin (a strong CYP3A inducer) with a single dose of PIQRAY 300 mg and alpelisib C max decreased by 59% and AUC by 74% following coadministration of rifampin (a strong CYP3A inducer) with PIQRAY 300 mg once daily.

Alpelisib AUC is predicted to decrease by 30% or less following coadministration of repeat doses of efavirenz (a moderate CYP3A inducer) with a single dose of PIQRAY 300 mg.

Other Drugs : No clinically significant differences in pharmacokinetics of the following drugs when coadministered with alpelisib: midazolam (a CYP3A substrate), repaglinide (a CYP2C8 substrate), warfarin (a CYP2C9 substrate), omeprazole (a CYP2C19 substrate), bupropion (a CYP2B6 substrate) and everolimus (a CYP3A and P-gp substrate).

In vitro Studies Transporter Systems : Alpelisib is a BCRP substrate.

Alpelisib is an inhibitor of P-gp but not of BCRP, MRP2, BSEP, OATP1B1, OATP1B3, OCT1, OAT1, OAT3, OCT2, MATE1, and MATE2K.

Adverse reactions

Adverse reactions (US label) US FDA label
  • The following adverse reactions are discussed in greater detail in other sections of the labeling: Severe Hypersensitivity [see Warnings and Precautions (5.1)] Severe Cutaneous Adverse Reactions [see Warnings and Precautions (5.2)] Hyperglycemia [see Warnings and Precautions (5.3)] Pneumonitis [see Warnings and Precautions (5.4)] Diarrhea or Colitis [see Warnings and Precautions (5.5)] Most common adverse reactions, including laboratory abnormalities (all Grades, incidence ≥ 20%) were increased glucose, increased creatinine, diarrhea, rash, decreased lymphocyte count, increased gamma-glutamyl transferase (GGT), nausea, increased alanine aminotransferase (ALT), fatigue, decreased hemoglobin, increased lipase, decreased appetite, stomatitis, vomiting, decreased weight, decreased calcium, decreased glucose, prolonged activated partial thromboplastin time (aPTT), and alopecia. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trial Experience

6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of PIQRAY was evaluated in a randomized, double-blind, placebo-controlled trial (SOLAR-1) in 571 patients with HR-positive, HER2-negative, advanced or metastatic breast cancer enrolled into two cohorts, with or without a PIK3CA mutation [see Clinical Studies (14)].

Patients received either PIQRAY 300 mg plus fulvestrant (n = 284) or placebo plus fulvestrant (n = 287). Fulvestrant 500 mg was administered intramuscularly on Cycle 1, Day 1 and 15, and then at Day 1 of each 28-day cycle during treatment phase. Two patients (0.7%) died while on treatment with PIQRAY plus fulvestrant due to causes other than the underlying malignancy.

Causes of death included one cardio-respiratory arrest and one second primary malignancy. Neither was suspected to be related to study treatment. Serious adverse reactions occurred in 35% of patients receiving PIQRAY plus fulvestrant. Serious adverse reactions in > 2% of patients receiving PIQRAY plus fulvestrant included hyperglycemia (10%), rash (3.5%), diarrhea (2.8%), acute kidney injury (2.5%), abdominal pain (2.1%), and anemia (2.1%).

Osteonecrosis of the jaw (ONJ) was reported in 4.2% of patients (12/284) in the PIQRAY plus fulvestrant arm compared to 1.4% of patients (4/287) in the placebo arm. All patients experiencing ONJ had prior or concomitant bisphosphonates or RANK-ligand inhibitor administration. Among patients receiving PIQRAY plus fulvestrant, 4.6% permanently discontinued both PIQRAY and fulvestrant and 21% permanently discontinued PIQRAY alone, due to adverse reactions.

The most frequent adverse reactions leading to treatment discontinuation of PIQRAY in > 2% patients receiving PIQRAY plus fulvestrant were hyperglycemia (6%), rash (4.2%), diarrhea (2.8%), and fatigue (2.5%). Dose reductions due to adverse reactions occurred in 55% of patients receiving PIQRAY plus fulvestrant. The most frequent adverse reactions leading to dose reduction in > 2% patients receiving PIQRAY plus fulvestrant were hyperglycemia (29%), rash (9%), diarrhea (6%), stomatitis (3.5%), and mucosal inflammation (2.1%).

The most common adverse reactions, including laboratory abnormalities (all grades, incidence ≥ 20%) were increased glucose, increased creatinine, diarrhea, rash, decreased lymphocyte count, increased gamma-glutamyl transferase (GGT), nausea, increased alanine aminotransferase (ALT), fatigue, decreased hemoglobin, increased lipase, decreased appetite, stomatitis, vomiting, decreased weight, decreased calcium, decreased glucose, prolonged activated partial thromboplastin time (aPTT), and alopecia. Adverse reactions and laboratory abnormalities are listed in Table 6 and Table 7, respectively.

Table 6: Adverse Reactions Occurring in ≥ 10% and ≥ 2% Higher than Placebo Arm in SOLAR-1 (All Grades) Grading according to CTCAE Version 4.03. 1 Stomatitis: including stomatitis, aphthous ulcer and mouth ulceration. 2 Abdominal pain: abdominal pain, abdominal pain upper, abdominal pain lower. 3 Fatigue: including fatigue, asthenia. 4 Mucosal dryness: including dry mouth, mucosal dryness, vulvovaginal dryness. 5 Urinary tract infection: including UTI and single case of urosepsis. 6 Dysgeusia: including dysgeusia, ageusia, hypogeusia. 7 Rash: including rash, rash maculo-papular, rash macular, rash generalized, rash papular, rash pruritic. 8 Dry skin: including dry skin, skin fissures, xerosis, xeroderma. * No Grade 4 adverse reactions were reported. PIQRAY plus fulvestrant N = 284 Placebo plus fulvestrant N = 287 Adverse reactions All Grades Grade 3-4 All Grades Grade 3-4 % % % % Gastrointestinal disorders Diarrhea 58 7 * 16 0.3 * Nausea 45 2.5 * 22 0.3 * Stomatitis 1 30 2.5 * 6 0 * Vomiting 27 0.7 * 10 0.3 * Abdominal pain 2 17 1.4 * 11 1 * Dyspepsia 11 0 * 6 0 * General disorders and administration site conditions Fatigue 3 42 5 * 29 1 * Mucosal inflammation 19 2.1 * 1 0 * Edema peripheral 15 0 * 5 0.3 * Pyrexia 14 0.7 4.9 0.3 * Mucosal dryness 4 12 0.4 * 4.2 0 * Infections and infestations Urinary tract infection 5 10 0.7 * 5 1 * Investigations Weight decreased 27 3.9 * 2.1 0 * Metabolism and nutrition disorders Decreased appetite 36 0.7 * 10 0.3 * Nervous system disorders Dysgeusia 6 18 0.4 * 3.5 0 * Headache 18 0.7 * 13 0 * Skin and subcutaneous tissue disorders Rash 7 52 20 * 7 0.3 * Alopecia 20 0 * 2.4 0 * Pruritus 18 0.7 * 6 0 * Dry skin 8 18 0.4 * 3.8 0 * Among the patients with Grade 2 or 3 rash, the median time to first onset of Grade 2 or 3 rash was 12 days.

A subgroup of 86 patients received premedication, including antihistamines, prior to onset of rash. In these patients, rash was reported less frequently than in the overall population, for all grades rash (27% vs 54%), Grade 3 rash (12% vs 20%) and rash leading to permanent discontinuation of PIQRAY (3.5% vs 4.2%). Of the 153 patients who experienced rash, 141 had resolution of the rash.

Table 7: Laboratory Abnormalities Occurring in ≥ 10% of Patients in SOLAR-1 1 Glucose increase is an expected laboratory abnormality of PI3K inhibition. * No Grade 4 laboratory abnormalities were reported. PIQRAY plus fulvestrant N = 284 Placebo plus fulvestrant N = 287 Laboratory abnormality All Grades Grade 3-4 All Grades Grade 3-4 % % % % Hematological parameters Lymphocyte count decreased 52 8 40 4.5 * Hemoglobin decreased 42 4.2 * 29 1 * aPTT prolonged 21 0.7 * 16 0.3 * Platelet count decreased 14 1.1 6 0 * Biochemical parameters Glucose increased 1 79 39 34 1 Creatinine increased 67 2.8 * 25 0.7 * GGT increased 52 11 44 10 ALT increased 44 3.5 34 2.4 * Lipase increased 42 7 25 6 Calcium (corrected) decreased 27 2.1 20 1.4 Glucose decreased 26 0.4 14 0 * Potassium decreased 14 6 2.8 0.7 * Albumin decreased 14 0 * 8 0 * Magnesium decreased 11 0.4 * 4.2 0 * Metformin Premedication for Hyperglycemia Adverse Reactions The safety of PIQRAY and endocrine therapy with metformin premedication was evaluated in METALLICA (NCT04300790), a single-arm, two-cohort study in 68 patients with HR-positive, HER2-negative advanced breast cancer harboring PIK3CA mutation(s).

The majority of patients (93%) received fulvestrant as endocrine therapy during the study. Cohort A enrolled patients with normal glycemic status (FPG < 100 mg/dl [< 5.6 mmol/L] and HbA1c < 5.7%) and Cohort B enrolled patients with impaired glycemic status (FPG 100–140 mg/dL [5.6–7.8 mmol/L] or HbA1c 5.7%–6.4%). Metformin was administered beginning 7 days prior to treatment with PIQRAY.

On Day 1 to Day 3, metformin 500 mg twice daily was administered orally and then increased up to 1,000 mg twice daily based on tolerability. Hyperglycemia adverse reactions occurred in 33% (16/48) and 70% (14/20 patients) in Cohort A and Cohort B, respectively. Grade 3-4 hyperglycemia occurred in 2.1% (1/48) of patients in Cohort A and 15% (3/20) of patients in Cohort B.

The incidence of nausea, vomiting, and diarrhea adverse reactions, including Grade 3 diarrhea, increases with metformin premedication [see Warnings and Precautions (5.3)]. Serious adverse reactions occurred in 22% of patients in the METALLICA study and serious adverse reactions ≥ 2% included diarrhea (3%), rash (3%) and vomiting (3%).

The most common Grade 3-4 adverse reactions (≥ 5%) were rash (16%), diarrhea (13%), and hyperglycemia (6%). Permanent discontinuation of PIQRAY due to adverse reactions in the METALLICA study occurred in 19% of patients, and dose modification or interruption of PIQRAY due to adverse reactions occurred in 56% of patients, of which 28% were dose reductions.

The most common adverse reactions (≥ 30%) in the METALLICA study were diarrhea (68%), nausea (68%), fatigue (46%), hyperglycemia (44%), rash (38%), and vomiting (34%).

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of PIQRAY. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Eye disorders: Uveitis Gastrointestinal disorders: Colitis Metabolism and nutrition disorders: Hyperglycemic hyperosmolar nonketotic syndrome (HHNKS).

Skin and subcutaneous tissue disorders: Angioedema, Drug reaction with eosinophilia and systemic symptoms (DRESS).

Adverse reaction frequency tables (US label) US FDA label
Table 6: Adverse Reactions Occurring in ≥ 10% and ≥ 2% Higher than Placebo Arm in SOLAR-1 (All Grades)
Grading according to CTCAE Version 4.03. 1Stomatitis: including stomatitis, aphthous ulcer and mouth ulceration. 2Abdominal pain: abdominal pain, abdominal pain upper, abdominal pain lower. 3Fatigue: including fatigue, asthenia. 4Mucosal dryness: including dry mouth, mucosal dryness, vulvovaginal dryness. 5Urinary tract infection: including UTI and single case of urosepsis. 6Dysgeusia: including dysgeusia, ageusia, hypogeusia. 7Rash: including rash, rash maculo-papular, rash macular, rash generalized, rash papular, rash pruritic. 8Dry skin: including dry skin, skin fissures, xerosis, xeroderma. *No Grade 4 adverse reactions were reported.
PIQRAY plus fulvestrant N = 284 Placebo plus fulvestrant N = 287
Adverse reactions All Grades Grade 3-4 All Grades Grade 3-4
% % % %
Gastrointestinal disorders
Diarrhea 58 7* 16 0.3*
Nausea 45 2.5* 22 0.3*
Stomatitis1 30 2.5* 6 0*
Vomiting 27 0.7* 10 0.3*
Abdominal pain2 17 1.4* 11 1*
Dyspepsia 11 0* 6 0*
General disorders and administration site conditions
Fatigue3 42 5* 29 1*
Mucosal inflammation 19 2.1* 1 0*
Edema peripheral 15 0* 5 0.3*
Pyrexia 14 0.7 4.9 0.3*
Mucosal dryness4 12 0.4* 4.2 0*
Infections and infestations
Urinary tract infection5 10 0.7* 5 1*
Investigations
Weight decreased 27 3.9* 2.1 0*
Metabolism and nutrition disorders
Decreased appetite 36 0.7* 10 0.3*
Nervous system disorders
Dysgeusia6 18 0.4* 3.5 0*
Headache 18 0.7* 13 0*
Skin and subcutaneous tissue disorders
Rash7 52 20* 7 0.3*
Alopecia 20 0* 2.4 0*
Pruritus 18 0.7* 6 0*
Dry skin8 18 0.4* 3.8 0*
Table 7: Laboratory Abnormalities Occurring in ≥ 10% of Patients in SOLAR-1
1Glucose increase is an expected laboratory abnormality of PI3K inhibition. *No Grade 4 laboratory abnormalities were reported.
PIQRAY plus fulvestrant N = 284 Placebo plus fulvestrant N = 287
Laboratory abnormality All Grades Grade 3-4 All Grades Grade 3-4
% % % %
Hematological parameters
Lymphocyte count decreased 52 8 40 4.5*
Hemoglobin decreased 42 4.2* 29 1*
aPTT prolonged 21 0.7* 16 0.3*
Platelet count decreased 14 1.1 6 0*
Biochemical parameters
Glucose increased1 79 39 34 1
Creatinine increased 67 2.8* 25 0.7*
GGT increased 52 11 44 10
ALT increased 44 3.5 34 2.4*
Lipase increased 42 7 25 6
Calcium (corrected) decreased 27 2.1 20 1.4
Glucose decreased 26 0.4 14 0*
Potassium decreased 14 6 2.8 0.7*
Albumin decreased 14 0* 8 0*
Magnesium decreased 11 0.4* 4.2 0*

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary PIQRAY is used in combination with fulvestrant. Refer to the Prescribing Information of fulvestrant for pregnancy information. Based on animal data and mechanism of action, PIQRAY can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. There are no available data in pregnant women to inform the drug-associated risk.

In animal reproduction studies, oral administration of alpelisib to pregnant rats and rabbits during organogenesis caused adverse developmental outcomes, including embryo-fetal mortality (post-implantation loss), reduced fetal weights, and increased incidences of fetal malformations at maternal exposures ≥ 0.8 times the exposure in humans based on AUC at the recommended dose of 300 mg/day (see Data). Advise pregnant women and females of reproductive potential of the potential risk to a fetus.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. However, the estimated background risk of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies in the U.S. general population. Data Animal Data In embryo-fetal development studies in rats and rabbits, pregnant animals received oral doses of alpelisib up to 30 mg/kg/day during the period of organogenesis.

In rats, oral administration of alpelisib resulted in maternal toxicity (body weight loss, low food consumption) and no viable fetuses (post-implantation loss) at 30 mg/kg/day (approximately 3 times the exposure in humans at the recommended dose of 300 mg/day based on AUC). At a dose of 10 mg/kg/day (approximately 0.8 times the exposure in humans at the recommended dose of 300 mg/day based on AUC), toxicities included reduced fetal weight and increased incidences of skeletal malformations (bent scapula and thickened or bent long bones) and fetal variations (enlarged brain ventricle, decreased bone ossification).

In a pilot embryo-fetal development study in rabbits, a dose of 30 mg/kg/day resulted in no viable fetuses (post-implantation loss). Doses ≥ 15 mg/kg/day resulted in increased embryo-fetal deaths, reduced fetal weights, and malformations, mostly related to the tail and head. At 15 mg/kg/day in rabbits, the maternal exposure was approximately 5 times the exposure achieved at the recommended human dose of 300 mg/day based on AUC.

Mechanism of action

12.1 Mechanism of Action Alpelisib is an inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity predominantly against PI3Kα. Gain-of-function mutations in the gene encoding the catalytic α-subunit of PI3K (PIK3CA) lead to activation of PI3Kα and Akt-signaling, cellular transformation and the generation of tumors in in vitro and in vivo models.

In breast cancer cell lines, alpelisib inhibited the phosphorylation of PI3K downstream targets, including Akt and showed activity in cell lines harboring a PIK3CA mutation. In vivo, alpelisib inhibited the PI3K/Akt signaling pathway and reduced tumor growth in xenograft models, including models of breast cancer. PI3K inhibition by alpelisib treatment has been shown to induce an increase in estrogen receptor (ER) transcription in breast cancer cells.

The combination of alpelisib and fulvestrant demonstrated increased anti-tumor activity compared to either treatment alone in xenograft models derived from ER-positive, PIK3CA mutated breast cancer cell lines.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Alpelisib exposure-response relationships and the time course of pharmacodynamic response are unknown. Cardiac Electrophysiology At the recommended PIQRAY 300 mg dose with or without fulvestrant, a mean increase in the QTc interval > 20 ms was not observed.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Elimination Alpelisib half-life is predicted to be 8 to 9 hours with clearance predicted to be 9.2 L/hr (21%) under fed conditions.

Excretion Following a single oral dose of 400 mg radiolabeled alpelisib under fasted condition, 81% of the administered dose was recovered in feces (36% unchanged, 32% BZG791) and 14% (2% unchanged, 7.1% BZG791) in urine.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics The population pharmacokinetics of alpelisib were evaluated in healthy subjects and adult patients with solid tumors at steady state and are presented as mean [coefficient of variation (CV%)], unless otherwise specified. In adult patients who received PIQRAY 300 mg once daily in SOLAR-1, alpelisib maximum plasma concentration (C max) is 2,480 (23%) ng/mL and AUC is 33,224 (21%) ng*h/mL.

Steady-state alpelisib C max and AUC increased in a dose proportional manner over the dose range of 30 mg to 450 mg (0.1 to 1.5 times the approved recommended dosage) under fed conditions. The mean accumulation of alpelisib is 1.3 to 1.5 and steady-state is reached within 3 days. Absorption The median time to maximum plasma concentration (T max) ranges between 2 to 4 hours.

Effect of Food Alpelisib AUC increased 1.7-fold and C max 1.8-fold following administration of a high-fat meal (985 calories with 58.1 g of fat) and AUC increased 1.8-fold and C max 2.4-fold following administration of a low-fat meal (334 calories with 8.7 g of fat). No clinically significant differences in alpelisib AUC were observed between low-fat and high-fat meals.

Distribution Alpelisib mean apparent volume of distribution is predicted to be 114 L (49%). Protein binding of alpelisib is 89% and is independent of concentration. Elimination Alpelisib half-life is predicted to be 8 to 9 hours with clearance predicted to be 9.2 L/hr (21%) under fed conditions. Metabolism Alpelisib is primarily metabolized by chemical and enzymatic hydrolysis to form its metabolite BZG791 and followed by CYP3A mediated hydroxylation.

Excretion Following a single oral dose of 400 mg radiolabeled alpelisib under fasted condition, 81% of the administered dose was recovered in feces (36% unchanged, 32% BZG791) and 14% (2% unchanged, 7.1% BZG791) in urine. CYP3A-mediated metabolites (12%) and glucuronides amounted to approximately 15% of the dose. Specific Populations No clinically significant differences in the pharmacokinetics of alpelisib were predicted based on age (21 to 87 years), sex, race/ethnicity (Japanese or White), body weight (37 to 181 kg), CLcr 30 to < 90 mL/min (based on the Cockcroft-Gault formula), or mild to severe hepatic impairment (Child-Pugh Class A, B, and C).

The effect of CLcr < 30 mL/min on the pharmacokinetics of alpelisib is unknown. Drug Interaction Studies Clinical Studies and Model-Informed Approaches Strong CYP3A Inhibitors: Alpelisib AUC is predicted to increase 1.4-fold or less following coadministration of repeat doses of ketoconazole (a strong CYP3A inhibitor). Strong and Moderate CYP3A Inducers: Alpelisib C max decreased by 38% and AUC by 57% following coadministration of repeat doses of rifampin (a strong CYP3A inducer) with a single dose of PIQRAY 300 mg and alpelisib C max decreased by 59% and AUC by 74% following coadministration of rifampin (a strong CYP3A inducer) with PIQRAY 300 mg once daily.

Alpelisib AUC is predicted to decrease by 30% or less following coadministration of repeat doses of efavirenz (a moderate CYP3A inducer) with a single dose of PIQRAY 300 mg. Acid Reducing Agents: Following coadministration of ranitidine (a H 2 receptor antagonist) Alpelisib AUC decreased by 21% and C max by 36% when administered with a low-fat meal (334 calories, 8.7 g fat).

Alpelisib AUC decreased by 30% and C max by 51% when administered in the fasted state. Other Drugs: No clinically significant differences in pharmacokinetics of the following drugs when coadministered with alpelisib: midazolam (a CYP3A substrate), repaglinide (a CYP2C8 substrate), warfarin (a CYP2C9 substrate), omeprazole (a CYP2C19 substrate), bupropion (a CYP2B6 substrate) and everolimus (a CYP3A and P-gp substrate).

In vitro Studies Transporter Systems: Alpelisib is a BCRP substrate. Alpelisib is an inhibitor of P-gp but not of BCRP, MRP2, BSEP, OATP1B1, OATP1B3, OCT1, OAT1, OAT3, OCT2, MATE1, and MATE2K.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. PIQRAY · Novartis Pharmaceuticals Corporation [US FDA-approved label, version 14, October 28, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b20b4e18-7a4b-4500-a08f-06c6dab0ee5b
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .